Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

Huang, Chung Feng; Huang, Jiun-Chi; Yang, Jeng‐Fu; Hsieh, Ming Yen; Lin, Zu Yau; Chen, Shinn Cherng; Wang, Liang Yen; Juo, Suh Hang Hank; Chen, Ku Chung; Chuang, Wan‐Long; Kuo, Hsing Tao; Dai, Chia Yen; Yu, Ming‐Lung

doi:10.1016/j.jhep.2011.03.029

Cited by 75 publications

(76 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…93 In East Asian HCV-1 patients who received 24 weeks of PEG-IFN α-2a plus RBV therapy, the IL-28B genotypes played a minor role to affect the overall SVR rates if they achieved RVR. 80,94,95 In line with the report by Thompson et al, IL-28B genotypes strongly affected the SVR rates in East Asian HCV-1 patients if they failed to achieve RVR. 96,98 However, the role of IL-28B genotypes was limited in East Asian HCV-1 patients who failed to achieve RVR if Wk-8R was taken into consideration.…”

Section: Impact Of Interleukin-28b Genotype On Viral Responses In Asisupporting

confidence: 68%

“…91,92 Furthermore, IL-28B genotypes are associated with the RVR rates in HCV-infected patients, especially in those with HCV-1 infection. 78,80,91,[93][94][95][96][97] Because the favorable IL-28 genotype highly predicts RVR and SVR in HCV-1 patients, Asian HCV-1 patients, who carry the highest frequency of the favorable IL-28B genotype, have greater SVR rates than HCV-1 patients of other ethnicities.…”

Section: Impact Of Interleukin-28b Genotype On Viral Responses In Asimentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

Liu¹,

Kao

2014

IJN

View full text Add to dashboard Cite

Asia is endemic for hepatitis C virus (HCV) infection, which is the leading cause of cirrhosis, hepatic decompensation, hepatocellular carcinoma, and liver transplantation worldwide. HCV has six major genotypes and each HCV genotype has its specific geographic distribution. HCV genotypes 1, 2, 3, and 6 are common in Asia. The aim of HCV treatment is to eradicate the virus by effective therapeutic agents; viral clearance is durable after long-term post-treatment follow-up. In most Asian countries, peginterferon alfa (PEG-IFN α) in combination with ribavirin remains the standard of care, and the overall sustained viral response (SVR) rate in Asian HCV patients is higher than that in Western patients. The differences are most significant in patients with HCV genotype 1 (HCV-1) infection, which is attributed to the higher frequency of IFN-responsive or favorable interleukin-28B (IL-28B) genotype in Asian populations than in other ethnic populations. In addition, the introduction of response-guided therapy, where the optimized treatment duration is based on the early viral kinetics during the first 12 weeks of treatment, increases the SVR rate. Recently, telaprevir or boceprevir-based triple therapy was found to further improve the SVR rate in treated and untreated HCV-1 patients and has become the new standard of care in Western and some Asian countries. Many novel direct-acting antiviral agents, either in combination with PEG-IFN α plus ribavirin or used as IFN-free regimens are under active investigation. At the time of this writing, simeprevir and sofosbuvir have been approved in the US. Because the SVR rates in Asian HCV patients receiving PEG-IFN α plus ribavirin therapy are high, health care providers should judiciously determine the clinical usefulness of these novel agents on the basis of treatment duration, anticipated viral responses, patient tolerance, financial burdens, and drug accessibility.

show abstract

Section: Impact Of Interleukin-28b Genotype On Viral Responses In Asisupporting

confidence: 68%

Section: Impact Of Interleukin-28b Genotype On Viral Responses In Asimentioning

confidence: 99%

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

Liu¹,

Kao

2014

IJN

View full text Add to dashboard Cite

show abstract

“…IL28B variations are associated with very early on-treatment viral kinetics in chronic hepatitis C patients who undergo interferon alfa-based therapy, and are the strongest pretreatment predictor of treatment response in patients infected with HCV GT-1 [19, 21–24]. Regarding the retreatment with peginterferon and ribavirin in chronic HCV GT-1 and GT-2 patients, the SVR rate for prior-relapser was quite good [25, 26].…”

Section: Interferon Supersensitive Groupmentioning

confidence: 99%

APASL consensus statements and recommendation on treatment of hepatitis C

et al. 2016

Self Cite

View full text Add to dashboard Cite

The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the “APASL consensus statements and recommendation on management of hepatitis C” in March, 2015, in order to revise “APASL consensus statements and management algorithms for hepatitis C virus infection (Hepatol Int 6:409–435, 2012)”. The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations on treatment of hepatitis C are presented in this review.Electronic supplementary materialThe online version of this article (doi:10.1007/s12072-016-9717-6) contains supplementary material, which is available to authorized users.

show abstract

“…HCV viral loads, although not associated with disease activity or progression to chronicity, have been associated with disease progression [157], development of HCC [158], and the treatment outcome of anti-HCV therapy with both interferon-based regimens [159,160] and new, powerful DAA interferon-free regimens [161]. Monitoring of viral loads during therapy has proven to be useful in individualized HCV therapy.…”

Section: #8 Consensus Statements and Recommendations On Prevention Ofmentioning

confidence: 99%

“…Combined with baseline viral loads, viral kinetics, and previous treatment responses [177], the IL28B genotype could provide important information for decision-making in clinical practice, including: (1) identification of HCV GT-1 treatment-naïve patients who are eligible for 24-week peginterferon/ribavirin (IL28B favorable genotype with baseline viral loads \400,000 IU/mL) [160], (2) early identification of HCV GT-1 nonresponders (IL28B unfavorable genotype with HCV RNA [1000 IU/mL at treatment week 4) [165], and (3) exclusion of retreatment with peginterferon/ribavirin for treatment-experienced HCV GT-1 patients who carry the IL28B unfavorable genotype [187].…”

Section: Host Genetic Testingmentioning

confidence: 99%

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

et al. 2016

Self Cite

View full text Add to dashboard Cite

The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on ''APASL consensus statements and recommendations for management of hepatitis C'' in March 2015 to revise the ''APASL consensus statements and management algorithms for hepatitis C virus infection'' (Hepatol Int 6:409-435, 2012). The working party consisted of expert hepatologists from the Asian-Pacific region gathered at the Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed, and debated during the course of drafting a revision. Participants of the consensus meeting assessed the quality of the cited studies. The finalized recommendations for hepatitis C prevention, epidemiology, and laboratory testing are presented in this review.

show abstract

Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

Cited by 75 publications

References 43 publications

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

APASL consensus statements and recommendation on treatment of hepatitis C

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

Contact Info

Product

Resources

About